CN112076148A - Nasal antiallergic gel and preparation method thereof - Google Patents
Nasal antiallergic gel and preparation method thereof Download PDFInfo
- Publication number
- CN112076148A CN112076148A CN201910504217.9A CN201910504217A CN112076148A CN 112076148 A CN112076148 A CN 112076148A CN 201910504217 A CN201910504217 A CN 201910504217A CN 112076148 A CN112076148 A CN 112076148A
- Authority
- CN
- China
- Prior art keywords
- nasal
- parts
- paraffin
- antiallergic gel
- antiallergic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003266 anti-allergic effect Effects 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 238000001879 gelation Methods 0.000 title description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 14
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 14
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 14
- 239000012188 paraffin wax Substances 0.000 claims description 19
- 235000019271 petrolatum Nutrition 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 17
- 229940099259 vaseline Drugs 0.000 claims description 15
- 229940057995 liquid paraffin Drugs 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- 239000004166 Lanolin Substances 0.000 claims description 11
- 229940039717 lanolin Drugs 0.000 claims description 11
- 235000019388 lanolin Nutrition 0.000 claims description 11
- 239000004264 Petrolatum Substances 0.000 claims description 10
- 229940066842 petrolatum Drugs 0.000 claims description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 9
- 229920002674 hyaluronan Polymers 0.000 claims description 9
- 229960003160 hyaluronic acid Drugs 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 8
- 239000001525 mentha piperita l. herb oil Substances 0.000 claims description 8
- 235000019477 peppermint oil Nutrition 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 6
- 239000003871 white petrolatum Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 2
- 235000019808 microcrystalline wax Nutrition 0.000 claims description 2
- 239000004200 microcrystalline wax Substances 0.000 claims description 2
- 235000019809 paraffin wax Nutrition 0.000 claims description 2
- 239000000428 dust Substances 0.000 abstract description 20
- 206010039085 Rhinitis allergic Diseases 0.000 abstract description 7
- 201000010105 allergic rhinitis Diseases 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 3
- 241000238876 Acari Species 0.000 abstract 1
- 206010028740 Nasal dryness Diseases 0.000 abstract 1
- 230000002421 anti-septic effect Effects 0.000 abstract 1
- 230000001932 seasonal effect Effects 0.000 abstract 1
- 210000003928 nasal cavity Anatomy 0.000 description 16
- 239000013566 allergen Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000001331 nose Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000002590 anti-leukotriene effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000013568 food allergen Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 244000309715 mini pig Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000004533 oil dispersion Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a nasal antiallergic gel containing sodium hyaluronate and a preparation method thereof. The gel is used for relieving seasonal or perennial inhalable allergic rhinitis and nasal dryness symptoms. For example: pollen, dust mites, etc. The product is easy to carry and convenient to use, and no antiseptic is added in the components, so that the safety is high.
Description
Technical Field
The invention relates to the technical field of antiallergic reagents, in particular to nasal antiallergic gel and a preparation method thereof.
Background
Allergic rhinitis is allergic rhinitis, and an allergen is an antigen that induces and reacts with a specific lgE antibody. They are mostly derived from animals, plants, insects, fungi or other allergic substances. Allergens are mainly classified into inhalant allergens and food allergens.
The method for treating allergic rhinitis comprises 1, drug treatment, such as antihistamine, glucocorticoid and anti-leukotriene, important drugs, and the curative effect can be different among different patients. After the medicine is stopped, the long-term continuous curative effect is not achieved, so that the sustained treatment of the persistent allergic rhinitis is required; 2. immunotherapy, inducing clinical and immunological tolerance, has long-term effect, and can prevent the development of allergic diseases. Allergen-specific immunotherapy is commonly administered by subcutaneous injection and sublingual administration. The treatment course is divided into a dose accumulation stage and a dose maintenance stage, and the total treatment course is not less than 2 years; 3. the indication of surgical treatment is that nasal obstruction symptoms are not improved through medicament or immunotherapy, and obvious physical signs are generated, so that the life quality is influenced; the nasal cavity has obvious anatomical variation accompanied with functional disorder; surgical treatment is not a routine treatment for allergic rhinitis; 4. Avoiding contact with allergens is simple and effective, but inhalant allergens are more difficult to avoid using conventional methods.
Based on the problems, the allergen blocking agent which is convenient to use, simple and effective is required to be developed at present, and the domestic emblazine is aqueous gel and has small adhesiveness.
Disclosure of Invention
Aiming at the problems in the prior art, the invention aims to provide a nasal antiallergic gel with excellent performance, which separates inhalation allergens such as dust, pollen and the like out and plays a role in separating the allergens by utilizing the physical adsorption effect of strong viscosity.
The purpose of the invention is realized by the following technical scheme:
the invention provides a nasal antiallergic gel, which is characterized by comprising the following components in parts by weight: 40-62 parts of solvent, 20-28 parts of paraffin, 10-30 parts of vaseline, 0.01-0.2 part of hyaluronic acid and 1.9-3 parts of lanolin.
Preferably, the weight part of the solvent is 40, 42, 45, 50, 55, 58 or 60 parts; the weight portion of the paraffin is 20, 21, 22, 23, 24, 25, 26, 27 or 28; the weight parts of the vaseline are 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 parts; the hyaluronic acid is 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19 or 0.2 part by weight; the lanolin comprises 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9 and 3 parts by weight.
Preferably, the paraffin wax is selected from one or more of solid paraffin wax and microcrystalline wax.
Preferably, the solvent is selected from liquid paraffin, and the liquid paraffin is liquid light paraffin.
Preferably, the petrolatum is selected from white petrolatum or yellow petrolatum.
Preferably, the nasal antiallergic gel further comprises a dementholized peppermint oil.
In a second aspect of the present invention, there is provided a method for preparing a nasal antiallergic gel, comprising the steps of:
1) adding vaseline, solid paraffin and lanolin into liquid paraffin, heating to 75-85 deg.C, and stirring until the solid is completely dissolved to obtain a first solution;
2) and cooling the first solution to 55-65 ℃, adding sodium hyaluronate, and uniformly stirring to obtain the nasal antiallergic gel.
Preferably, the sodium hyaluronate is oil-dispersed hyaluronic acid.
Preferably, the step 2) includes: and cooling the first solution to 55-65 ℃, adding oil-dispersed sodium hyaluronate and dementholized peppermint oil, and uniformly stirring to obtain the nasal antiallergic gel.
Preferably, the oil dispersion sodium hyaluronate is prepared from sodium hyaluronate and vegetable oil by a special process, and the main functional component sodium hyaluronate is uniformly dispersed in the oil in a microsphere form.
Compared with the prior art, the invention has the beneficial effects that:
the nasal antiallergic gel provided by the invention separates the inhalation allergens such as dust, pollen and the like outside by utilizing the physical adsorption effect with extremely strong viscosity, and plays a role in separating the allergens
The nasal antiallergic gel provided by the invention is simple in preparation process, convenient to use, simple, effective, free of side effects and capable of obviously improving the life quality of patients.
Drawings
FIG. 1A is a nasal cavity view after washing;
fig. 1B is a nasal examination of the placebo group one week later;
fig. 1C is a nasal examination image of experimental group 1 after one week;
fig. 1D is a nasal examination of experimental group 2 one week later;
fig. 1E is a nasal examination of experimental group 3 after one week;
fig. 1F is a nasal examination of experimental group 4 after one week.
Detailed Description
The present invention is further illustrated by the following examples, which are not intended to limit the scope of the present invention, and any modifications and variations thereof within the spirit of the present invention will be apparent to those skilled in the art.
Example one
The embodiment provides a nasal antiallergic gel, which comprises the following components in parts by weight: 40 parts of liquid paraffin, 20 parts of solid paraffin, 10 parts of vaseline, 0.01 part of hyaluronic acid and 0.2 part of lanolin. The vaseline is selected from white vaseline or yellow vaseline.
The present invention further provides a method for preparing a nasal antiallergic gel, comprising the following steps:
1) adding vaseline, solid paraffin and lanolin into liquid paraffin, heating to 75-85 deg.C, and stirring until the solid is completely dissolved to obtain a first solution;
2) and cooling the first solution to 55-65 ℃, adding oil-dispersed sodium hyaluronate, and uniformly stirring to obtain the nasal antiallergic gel.
Example two
The embodiment provides a nasal antiallergic gel, which comprises the following components in parts by weight: 58 parts of liquid paraffin, 23 parts of solid paraffin, 15 parts of vaseline, 0.02 part of oil-dispersed hyaluronic acid, 3 parts of lanolin and 0.03 part of dementholized peppermint oil. The petrolatum of this example is selected from white petrolatum or yellow petrolatum.
The present invention further provides a method for preparing a nasal antiallergic gel, comprising the following steps:
1) adding vaseline, solid paraffin and lanolin into liquid paraffin, heating to 75-85 deg.C, and stirring until the solid is completely dissolved to obtain a first solution;
2) and cooling the first solution to 55-65 ℃, adding oil-dispersed sodium hyaluronate and dementholized peppermint oil, and uniformly stirring to obtain the nasal antiallergic gel.
EXAMPLE III
The embodiment provides a nasal antiallergic gel, which comprises the following components in parts by weight: 60 parts of liquid paraffin, 20 parts of solid paraffin, 18 parts of vaseline, 0.1 part of oil-dispersed hyaluronic acid, 1.9 parts of lanolin and 0.01 part of dementholized peppermint oil. The petrolatum of this example is selected from white petrolatum or yellow petrolatum.
The present invention further provides a method for preparing a nasal antiallergic gel, comprising the following steps:
1) adding vaseline, solid paraffin and lanolin into liquid paraffin, heating to 75-85 deg.C, and stirring until the solid is completely dissolved to obtain a first solution;
2) and cooling the first solution to 55-65 ℃, adding oil-dispersed sodium hyaluronate and dementholized peppermint oil, and uniformly stirring to obtain the nasal antiallergic gel.
Example four
The embodiment provides a nasal antiallergic gel, which comprises the following components in parts by weight: 62 parts of liquid paraffin, 22 parts of solid paraffin, 16 parts of vaseline and 0.1 part of oil-dispersed hyaluronic acid. The petrolatum of this example is selected from white petrolatum or yellow petrolatum.
The present invention further provides a method for preparing a nasal antiallergic gel, comprising the following steps:
1) adding vaseline and solid paraffin into liquid paraffin, heating to 75-85 deg.C, stirring until the solid is completely dissolved to obtain a first solution;
2) and cooling the first solution to 55-65 ℃, adding oil-dispersed sodium hyaluronate, and uniformly stirring to obtain the nasal antiallergic gel.
And (3) effectiveness evaluation:
1. purpose of the experiment: the dust concentration in the air is simulated, the dust adhesion capacity of the nasal cavity is detected, and the effectiveness of the product is verified.
2. The instrument comprises the following steps: notebook computer and nose endoscope
3. Sample preparation: the products described in example one, example two, example three and example four.
4. Subject: 5 Bama miniature pigs are divided into five groups, namely a blank control group, an experimental group 1, an experimental group 2, an experimental group 3 and an experimental group 4.
5. The experimental method comprises the following steps:
1) preparing a sample, namely taking the products prepared in the first embodiment, the second embodiment, the third embodiment and the fourth embodiment of the invention;
2) washing nasal cavities of pigs with physiological saline respectively, and detecting nasal cavity symptoms with an endoscope after the nasal cavities are washed;
3) uniformly applying the products prepared in the first, second, third and fourth examples to one nostril of experiment groups 1, 2, 3 and 4 for a week, and leaving the other nostril untreated;
4) the same amount of powder is taken to simulate the environment with high dust concentration in the air, and the absorption effect of the powder on the dust is detected by using an intranasal endoscope.
6. The experimental results are as follows:
experimental results referring to fig. 1A-1F, fig. 1A is a nasal cavity examination image after washing, showing that the inner wall of the nasal cavity is clean and smooth; fig. 1B is a nasal examination of the blank control group one week later showing a small amount of dust adhering to the inner wall; FIG. 1C is a nasal examination image of experimental group 1 after one week, showing a layer of dust adhering to the inner wall of experimental group 1; FIG. 1D is a nasal examination image of experimental group 2 one week later showing a layer of dust adhering to the inner wall of experimental group 2; FIG. 1E is a nasal examination image of experimental group 3 after one week, showing a layer of dust adhering to the inner wall of experimental group 3; FIG. 1F is a nasal examination of experimental group 4 one week later showing a layer of dust adhering to the inner wall of experimental group 4;
7. and (3) analyzing experimental data:
the Area of dust adhesion (Area) and the Integrated Optical Density (IOD) of 4 products were calculated using image-Pro Plus, whereby the magnitude of the adhesion properties of the reaction products:
TABLE 1 dust adhesion nasal cavity area analysis data chart
| Product name | Area of dust adhesion | Integral optical density |
| Experimental group 1 | 47112.7±3511.9 | 17390.7±1234.7 |
| Experimental group 2 | 42312.7±3612.5 | 16190.7±1524.5 |
| Experimental group 3 | 33356.7±3732.8 | 15807.7±2754.3 |
| Experimental group 4 | 37448.7±3381.5 | 16266.3±1811.1 |
| Blank control | 9126.0±486.1 | 3873.0±135.9 |
8. And (4) experimental conclusion:
as can be seen from fig. 1A to 1F, most of the dust entering the nasal cavity after the product is applied is adhered to the periphery of the nasal cavity by the product, and only a very small amount of dust in the nasal cavity without the product is adhered to the inner wall of the nose by the nasal cilia and nasal secretion, which shows that the dust adhesion of the nasal cavity after the product is applied is obviously increased. Table 1 shows that the area of the nasal cavity adhered with dust and the integrated optical density are calculated by using Image-Pro to analyze data of the picture, and the area of the nasal cavity adhered with dust and the integrated optical density are far greater than those of the blank contrast, which shows that the product has strong adhesiveness, can reduce the absorption of particles into the nasal cavity through the adhesiveness, and plays a role in relieving anaphylaxis caused by allergic rhinitis and allergic asthma.
The foregoing is a more detailed description of the invention in connection with specific preferred embodiments and it is not intended that the invention be limited to these specific details. For those skilled in the art to which the invention pertains, several simple deductions or substitutions can be made without departing from the spirit of the invention, and all shall be considered as belonging to the protection scope of the invention.
Claims (8)
1. The nasal antiallergic gel is characterized by comprising the following components in parts by weight: 40-62 parts of solvent, 20-28 parts of paraffin, 10-30 parts of vaseline, 0.01-0.2 part of hyaluronic acid and 1.9-3 parts of lanolin.
2. The nasal antiallergic gel as claimed in claim 1, wherein the paraffin is selected from one or more of paraffin wax and microcrystalline wax.
3. The nasal antiallergic gel as claimed in claim 1, wherein the solvent is selected from liquid paraffin, and the liquid paraffin is liquid light paraffin.
4. The nasal antiallergic gel according to claim 1, wherein the petrolatum is selected from white petrolatum or yellow petrolatum.
5. The nasal antiallergic gel according to claim 1, characterized in that it further comprises dementholized peppermint oil.
6. A preparation method of a nasal antiallergic gel is characterized by comprising the following steps:
adding vaseline, solid paraffin and lanolin into liquid paraffin, heating to 75-85 deg.C, and stirring until the solid is completely dissolved to obtain a first solution;
and cooling the first solution to 55-65 ℃, adding sodium hyaluronate, and uniformly stirring to obtain the nasal antiallergic gel.
7. The method of claim 5, wherein the sodium hyaluronate is oil-dispersed hyaluronic acid.
8. The method for preparing a nasal antiallergic gel according to claim 5, wherein the step 2) comprises: and cooling the first solution to 55-65 ℃, adding oil-dispersed sodium hyaluronate and dementholized peppermint oil, and uniformly stirring to obtain the nasal antiallergic gel.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910504217.9A CN112076148A (en) | 2019-06-12 | 2019-06-12 | Nasal antiallergic gel and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910504217.9A CN112076148A (en) | 2019-06-12 | 2019-06-12 | Nasal antiallergic gel and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112076148A true CN112076148A (en) | 2020-12-15 |
Family
ID=73733206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910504217.9A Pending CN112076148A (en) | 2019-06-12 | 2019-06-12 | Nasal antiallergic gel and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112076148A (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020082305A1 (en) * | 2000-05-31 | 2002-06-27 | Peter Theiss | Petrolatum-based nose ointment |
| DE10360425A1 (en) * | 2003-12-19 | 2005-07-28 | Ursapharm Arzneimittel Gmbh & Co. Kg | Compositions containing hyaluronic acid or its derivatives as sole active agent, useful for topical treatment of ophthalmological or rhinological allergic complications |
| JP2010111638A (en) * | 2008-11-07 | 2010-05-20 | Earth Chem Corp Ltd | Liniment for intranasal application |
| CN102764230A (en) * | 2011-05-06 | 2012-11-07 | 上海现代制药股份有限公司 | Nasal gel or ointment preparation for preventing and/or treating aspiration allergy |
| CN104069130A (en) * | 2013-03-25 | 2014-10-01 | 方翔 | Allergen obstructing agent for respiratory tract and preparation method thereof |
| CN104510631A (en) * | 2013-09-27 | 2015-04-15 | 华熙福瑞达生物医药有限公司 | Oil-dispersed sodium hyaluronate and preparation method and application of same |
| CN107432872A (en) * | 2017-07-25 | 2017-12-05 | 上海科进医疗科技有限公司 | A kind of pollen barrier and its preparation method and application |
| CN107510688A (en) * | 2016-06-14 | 2017-12-26 | 陕西合成药业股份有限公司 | It is a kind of to obstruct the former emulsifiable paste of nasal allergy |
| CN109010427A (en) * | 2018-08-30 | 2018-12-18 | 毕青玲 | A kind of schneiderian membrance moisturizing microemulsion and preparation method thereof |
-
2019
- 2019-06-12 CN CN201910504217.9A patent/CN112076148A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020082305A1 (en) * | 2000-05-31 | 2002-06-27 | Peter Theiss | Petrolatum-based nose ointment |
| DE10360425A1 (en) * | 2003-12-19 | 2005-07-28 | Ursapharm Arzneimittel Gmbh & Co. Kg | Compositions containing hyaluronic acid or its derivatives as sole active agent, useful for topical treatment of ophthalmological or rhinological allergic complications |
| JP2010111638A (en) * | 2008-11-07 | 2010-05-20 | Earth Chem Corp Ltd | Liniment for intranasal application |
| CN102764230A (en) * | 2011-05-06 | 2012-11-07 | 上海现代制药股份有限公司 | Nasal gel or ointment preparation for preventing and/or treating aspiration allergy |
| CN104069130A (en) * | 2013-03-25 | 2014-10-01 | 方翔 | Allergen obstructing agent for respiratory tract and preparation method thereof |
| CN104510631A (en) * | 2013-09-27 | 2015-04-15 | 华熙福瑞达生物医药有限公司 | Oil-dispersed sodium hyaluronate and preparation method and application of same |
| CN107510688A (en) * | 2016-06-14 | 2017-12-26 | 陕西合成药业股份有限公司 | It is a kind of to obstruct the former emulsifiable paste of nasal allergy |
| CN107432872A (en) * | 2017-07-25 | 2017-12-05 | 上海科进医疗科技有限公司 | A kind of pollen barrier and its preparation method and application |
| CN109010427A (en) * | 2018-08-30 | 2018-12-18 | 毕青玲 | A kind of schneiderian membrance moisturizing microemulsion and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kowalski et al. | Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement | |
| Andersson et al. | Inhibition of the dermal immediate allergic reaction through prolonged treatment with topical glucocorticosteroids | |
| Hendrick et al. | Formalin asthma in hospital staff. | |
| McFadden Jr | A century of asthma | |
| Waclawski et al. | Occupational asthma in nurses caused by chlorhexidine and alcohol aerosols. | |
| Wu et al. | Anti-ST2 nanoparticle alleviates lung inflammation by targeting ILC2s-CD4+ T response | |
| WO2008102151A1 (en) | Medical uses of glucans | |
| CN112076148A (en) | Nasal antiallergic gel and preparation method thereof | |
| Huber et al. | Adverse reactions to latex products: preventive and therapeutic strategies | |
| Agrawaal et al. | Clinico-epidemiological Study on Pesticide Poisoning in a Tertiary Care Hospital in Eastern Nepal. | |
| CN101829154B (en) | Preparation method of medicine composition for preventing and treating asthma | |
| Bircher | Drug allergens | |
| CN108201526A (en) | A kind of gel for treating rhinitis and its preparation method and application | |
| D’Amato et al. | Nasal filters in prevention of seasonal rhinitis induced by allergenic pollen grains. Open clinical study | |
| Rose et al. | Safety, tolerability, and impact on allergic inflammation of autologous E. coli autovaccine in the treatment of house dust mite asthma-a prospective open clinical trial | |
| Haahtela et al. | Non‐specific reactions caused by diluents containing glycerol in nasal and bronchial challenge tests | |
| JPH06510752A (en) | How to use Substance P for allergy treatment | |
| TWI480044B (en) | A high molecular weight heparin or low molecular weight heparin for the preparation of a composition for at least two consecutive days of administration to improve the allergic constitution | |
| Connell | Nasal hypersensitivity | |
| Liu et al. | Analysis of the efficacy of azelastine nasal spray combined with mussel mucin in the treatment of allergic rhinitis and the influence of peripheral blood CCL26 and CCR3 levels. | |
| Manab et al. | Efficacy of intranasal honey spray:'As an adjunct treatment for allergic rhinitis' | |
| Li et al. | Influence of Broncho-Vaxom Immunotherapy Combined with Trelegy Ellipta on Blood Eosinophils in Patients with Chronic Obstructive Pulmonary Disease. | |
| Ramzan et al. | Effect of Beclomethasone Dipropionate Versus Mast Cell Stabilizer on Mucociliary Clearance in Patients of Allergic Rhinitis | |
| Waldbott | Allergic shock from local and general anesthetics | |
| Twentyman et al. | Reversibility of the allergen‐provoked late asthmatic response by an inhaled β2‐adrenoceptor agonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |